Diagnosis for Aripiprazole Augmentation in Treatment-Resistant Depression
The primary diagnosis should remain "Major Depressive Disorder" (MDD), with documentation specifying "inadequate response to antidepressant therapy" or "treatment-resistant depression" to justify aripiprazole augmentation. This is the FDA-approved indication and the diagnosis supported by clinical trial evidence 1, 2.
Diagnostic Documentation Framework
Primary Diagnosis Code
- Major Depressive Disorder (F33.x for recurrent, F32.x for single episode)
- Add specifier: "with inadequate response to antidepressant treatment"
Required Documentation Elements
Before prescribing aripiprazole augmentation, document:
Current depressive episode severity using standardized scales (MADRS ≥15 or HAM-D score) 3
Current antidepressant regimen: Document the specific SSRI, SNRI, or other antidepressant being continued (escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, or bupropion) 1, 2
Clinical Context
The evidence strongly supports aripiprazole as adjunctive therapy to ongoing antidepressants, not as monotherapy for depression 1, 2, 6. The FDA label explicitly states approval for "adjunctive treatment of Major Depressive Disorder" 1. Clinical trials consistently defined the population as patients with MDD who had inadequate response to 1-2 antidepressant trials 2, 7.
Important Distinction from Other Uses
Do not use diagnoses from schizophrenia guidelines 8, 9, 8, 9, 8, 9: The evidence provided about aripiprazole augmentation in schizophrenia (for negative symptoms or clozapine augmentation) is not applicable to your depression treatment scenario. These are entirely different clinical contexts with different mechanisms and indications.
Practical Documentation Template
Diagnosis: Major Depressive Disorder, recurrent episode, moderate-to-severe, with inadequate response to antidepressant monotherapy
Treatment History:
- Failed trial #1: [Drug name, dose, duration ≥4 weeks]
- Failed trial #2: [Drug name, dose, duration ≥4 weeks] (if applicable)
- Current antidepressant: [Drug name, dose]
Rationale for augmentation: Patient meets criteria for treatment-resistant depression with persistent depressive symptoms (MADRS score ≥15 or equivalent) despite adequate antidepressant trial(s). Aripiprazole augmentation FDA-approved for this indication.
Dosing Considerations for Documentation
Starting dose: 2-5 mg daily 10, 11: Recent meta-analysis suggests optimal efficacy at low doses (2-5 mg), with no additional benefit at higher doses up to 20 mg 10. The FDA label allows 2-20 mg/day 1, but starting at 2.5 mg reduces akathisia risk by 50% 11.
Common Pitfalls to Avoid
Do not diagnose "Bipolar Disorder" unless truly present: While aripiprazole is effective for bipolar depression 12, inappropriately changing the diagnosis to justify prescribing creates documentation and insurance problems.
Do not use "off-label" coding: Aripiprazole augmentation for MDD is FDA-approved 1, so this is on-label use when properly documented.
Do not omit documentation of failed trials: Insurance often requires proof of treatment resistance (failed antidepressant trials) before approving aripiprazole for depression 3.
Monitor and document side effects: Akathisia occurs in 25% of patients 1, 2, Parkinsonism in 17% 7, and weight gain is possible 1. Document baseline weight, movement assessment, and metabolic parameters 1.
Expected Outcomes
Remission rates with aripiprazole augmentation: 36-44% versus 18-29% with placebo 2, 7. Response often occurs within 1-2 weeks 11, with 82% of eventual remitters achieving remission by week 10 13. Number needed to treat: 6.6 7.